Theralase Technologies Statistics

Total Valuation

Theralase Technologies has a market cap or net worth of CAD 61.95 million. The enterprise value is 61.93 million.

Market Cap	61.95M
Enterprise Value	61.93M

Important Dates

The last earnings date was Friday, November 29, 2024.

Earnings Date	Nov 29, 2024
Ex-Dividend Date	n/a

Share Statistics

Theralase Technologies has 247.78 million shares outstanding. The number of shares has increased by 7.23% in one year.

Current Share Class	n/a
Shares Outstanding	247.78M
Shares Change (YoY)	+7.23%
Shares Change (QoQ)	+1.18%
Owned by Insiders (%)	6.85%
Owned by Institutions (%)	0.17%
Float	230.80M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	58.93
PB Ratio	28.70
P/TBV Ratio	28.96
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-14.31
EV / Sales	62.77
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-14.96

Financial Position

The company has a current ratio of 1.91, with a Debt / Equity ratio of 0.15.

Current Ratio	1.91
Quick Ratio	1.10
Debt / Equity	0.15
Debt / EBITDA	n/a
Debt / FCF	-0.08
Interest Coverage	-169.50

Financial Efficiency

Return on equity (ROE) is -229.60% and return on invested capital (ROIC) is -121.27%.

Return on Equity (ROE)	-229.60%
Return on Assets (ROA)	-87.66%
Return on Capital (ROIC)	-121.27%
Revenue Per Employee	49,330
Profits Per Employee	-216,451
Employee Count	20
Asset Turnover	0.32
Inventory Turnover	0.83

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +51.52% in the last 52 weeks. The beta is 1.36, so Theralase Technologies's price volatility has been higher than the market average.

Beta (5Y)	1.36
52-Week Price Change	+51.52%
50-Day Moving Average	0.27
200-Day Moving Average	0.20
Relative Strength Index (RSI)	45.89
Average Volume (20 Days)	122,444

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Theralase Technologies had revenue of CAD 986,596 and -4.33 million in losses. Loss per share was -0.02.

Revenue	986,596
Gross Profit	510,169
Operating Income	-4.36M
Pretax Income	-4.33M
Net Income	-4.33M
EBITDA	-4.18M
EBIT	-4.36M
Loss Per Share	-0.02

Full Income Statement

Balance Sheet

The company has 329,504 in cash and 317,733 in debt, giving a net cash position of 11,771 or 0.00 per share.

Cash & Cash Equivalents	329,504
Total Debt	317,733
Net Cash	11,771
Net Cash Per Share	0.00
Equity (Book Value)	2.14M
Book Value Per Share	0.01
Working Capital	788,440

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -4.12 million and capital expenditures -24,484, giving a free cash flow of -4.14 million.

Operating Cash Flow	-4.12M
Capital Expenditures	-24,484
Free Cash Flow	-4.14M
FCF Per Share	-0.02

Full Cash Flow Statement

Margins

Gross Margin	51.71%
Operating Margin	-442.29%
Pretax Margin	-438.78%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Theralase Technologies does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.23%
Shareholder Yield	-7.23%
Earnings Yield	-7.45%
FCF Yield	-6.68%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Theralase Technologies has an Altman Z-Score of -8.92. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.92
Piotroski F-Score	n/a